• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Io Biotech Inc.

Headquarters: Copenhagen, Denmark
Website: http://www.iobiotech.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Mai-Britt Zocca, PhD
Number Of Employees: 80
Enterprise Value: $2,494,441
PE Ratio: -0.69
Exchange/Ticker 1: NASDAQ:IOBT
Exchange/Ticker 2: N/A
Latest Market Cap: $65,880,896

BioCentury | Apr 16, 2024
Management Tracks

Viatris hires Corinne Le Goff as commercial head

Plus: Exact, Obsidian name new CFOs and updates from Applied, Faron, Athira and more
Read More
BioCentury | Apr 8, 2024
Management Tracks

Chi Li to lead regulatory at Curevo

Plus: Zura names Robert Lisicki as CEO, and updates from Faron, IO, PanTher and Precision
Read More
BioCentury | Jan 5, 2024
Management Tracks

Friedman succeeding Hoos at Scorpion

Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
Read More
BioCentury | Aug 8, 2023
Deals

Aug. 7 Quick Takes: Eyeing cash, Ikena buys Pionyr 

Plus: Astellas’ Zimura approved for geographic atrophy, Bavarian’s chikungunya vaccine heading to regulators and updates from Gracell, IO, Sage, Nektar and DotBio
Read More
BioCentury | Oct 13, 2022
Management Tracks

Maag becomes CEO at Kyverna

Plus Bernstein to head R&D at Maze, and updates from Visiox, Araris, Quest and Biohaven
Read More
BioCentury | Apr 12, 2022
Product Development

AACR Quick Takes: Affimed impresses with NK cell/bispecific antibody combination

Plus: Bicycle’s tox problem, updates from IO Biotech, Innovent
Read More
BioCentury | Apr 7, 2022
Finance

Lundbeck VC unit narrows focus to Denmark, aims to scale local ecosystem

Newly rechristened Lundbeckfonden BioCapital will take advantage of maturing Danish sector while further building it
Read More
BioCentury | Feb 19, 2022
Data Byte

Moderna’s mRNA vaccine adds to a short IDO pipeline

Moderna’s candidate aims to stimulate T cell responses to IDO1 and PD-L1
Read More
BioCentury | Dec 22, 2021
Product Development

PD-1’s new narrative – a bonanza of innovation

Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
Read More
BioCentury | Dec 10, 2021
Product Development

Dec. 9 Quick Takes: $67.5M A round for liquid biopsy play Exai

Plus: FDA delivers RWE guidance, ACT for ALS clears House and more
Read More
Items per page:
1 - 10 of 11
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa